Weight change and glycemic control in type 2 diabetes patients during COVID-19 pandemic: the lockdown effect

Biamonte, Emilia; Pegoraro, Francesco; Carrone, Flaminia; Facchi, Isabella; Favacchio, Giuseppe; Lania, Andrea; Mazziotti, Gherardo; Mirani, Marco

doi:10.1007/s12020-021-02739-5

Cited by 65 publications

(94 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In surveys of UK adults conducted during the first lockdown (April--May 2020), participants reported adverse changes in several behaviours that promote weight gain (adverse changes in diet, physical activity, alcohol consumption, mental health and sleep quality). 27 28 Some [29][30][31] but not all studies 32 33 in people with T2D have shown worsening of glycaemic control in relation to COVID-19 lockdown which could explain the increased rates of insulin prescribing we observed between March and December 2020.…”

Section: Discussionmentioning

confidence: 89%

Impact of COVID-19 restrictions on diabetes health checks and prescribing for people with type 2 diabetes: a UK-wide cohort study involving 618 161 people in primary care

et al. 2021

View full text Add to dashboard Cite

ObjectiveTo compare rates of performing National Institute for Health and Care Excellence-recommended health checks and prescribing in people with type 2 diabetes (T2D), before and after the first COVID-19 peak in March 2020, and to assess whether trends varied by age, sex, ethnicity and deprivation.MethodsWe studied 618 161 people with T2D followed between March and December 2020 from 1744 UK general practices registered with the Clinical Practice Research Datalink. We focused on six health checks: haemoglobin A1c, serum creatinine, cholesterol, urinary albumin excretion, blood pressure and body mass index assessment. Regression models compared observed rates in April 2020 and between March and December 2020 with trend-adjusted expected rates derived from 10-year historical data.ResultsIn April 2020, in English practices, rates of performing health checks were reduced by 76%–88% when compared with 10-year historical trends, with older people from deprived areas experiencing the greatest reductions. Between May and December 2020, the reduced rates recovered gradually but overall remained 28%–47% lower, with similar findings in other UK nations. Extrapolated to the UK population, there were ~7.4 million fewer care processes undertaken March–December 2020. In England, rates for new medication fell during April with reductions varying from 10% (95% CI: 4% to 16%) for antiplatelet agents to 60% (95% CI: 58% to 62%) for antidiabetic medications. Overall, between March and December 2020, the rate of prescribing new diabetes medications fell by 19% (95% CI: 15% to 22%) and new antihypertensive medication prescribing fell by 22% (95% CI: 18% to 26%), but prescribing of new lipid-lowering or antiplatelet therapy was unchanged. Similar trends were observed across the UK, except for a reduction in new lipid-lowering therapy prescribing in the other UK nations (reduction: 16% (95% CI: 10% to 21%)). Extrapolated to the UK population, between March and December 2020, there were ~31 800 fewer people with T2D prescribed a new type of diabetes medication and ~14 600 fewer prescribed a new type of antihypertensive medication.ConclusionsOver the coming months, healthcare services will need to manage this backlog of testing and prescribing. We recommend effective communications to ensure patient engagement with diabetes services, monitoring and opportunities for prescribing, and when appropriate use of home monitoring, remote consultations and other innovations in care.

show abstract

Section: Discussionmentioning

confidence: 89%

Impact of COVID-19 restrictions on diabetes health checks and prescribing for people with type 2 diabetes: a UK-wide cohort study involving 618 161 people in primary care

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In the BCSs involved in this study, the lifestyle intervention adherence was associated with a slight improvement in BMI (−1.7%) as well as body weight (−1.2%). As being overweight (≥25 to <30 kg/m 2 ) is associated with increased adiposity, particularly visceral adipose tissue, a slight amelioration in body composition could also induce a beneficial effect on cardiometabolic parameters, especially during COVID-19 quarantine, when a worsening in lifestyle routine is expected [ 37 , 70 , 71 ]. Importantly, the Mediterranean diet proposed in our study was not considered as a weight loss plan, but was beneficial for heart health, decreasing the risk of cardiometabolic disease and potential influence on BC prognosis and prevention of recurrences or secondarisms [ 72 ].…”

Section: Discussionmentioning

confidence: 99%

Effects of a Home-Based Lifestyle Intervention Program on Cardiometabolic Health in Breast Cancer Survivors during the COVID-19 Lockdown

Natalucci

Marini

Flori

et al. 2021

JCM

View full text Add to dashboard Cite

This study aimed to evaluate the cardiometabolic effects of a home-based lifestyle intervention (LI) in breast cancer survivors (BCSs) during the COVID-19 lockdown. In total, 30 BCSs (women; stages 0–II; non-metastatic; aged 53.5 ± 7.6 years; non-physically active; normal left ventricular systolic function) with a risk factor for recurrence underwent a 3-month LI based on nutrition and exercise. Anthropometrics, Mediterranean diet adherence, physical activity level (PAL), cardiorespiratory fitness (VO2max), echocardiographic parameters, heart rate variability (average standard deviation of NN intervals (ASDNN/5 min) and 24 h very- (24 hVLF) and low-frequency (24 hLF)), and metabolic, endocrine, and inflammatory serum biomarkers (glycemia, insulin resistance, progesterone, testosterone, and high-sensitivity C-reactive protein (hs-CRP)) were evaluated before (T0) and after (T1) the LI. After the LI, there were improvements in: body mass index (kg/m2: T0 = 26.0 ± 5.0, T1 = 25.5 ± 4.7; p = 0.035); diet (Mediet score: T0 = 6.9 ± 2.3, T1 = 8.8 ± 2.2; p < 0.001); PAL (MET-min/week: T0 = 647 ± 547, T1 = 1043 ± 564; p < 0.001); VO2max (mL·min−1·kg−1: T0 = 30.5 ± 5.8, T1 = 33.4 ± 6.8; p < 0.001); signs of diastolic dysfunction (participants: T0 = 15, T1 = 10; p = 0.007); AS-DNN/5 min (ms: T0 = 50.6 ± 14.4, T1 = 55.3 ± 16.7; p = 0.032); 24 hLF (ms2: T0 = 589 ± 391, T1 = 732 ± 542; p = 0.014); glycemia (mg/dL: T0 = 100.8 ± 11.4, T1 = 91.7 ± 11.0; p < 0.001); insulin resistance (HOMA-IR score: T0 = 2.07 ± 1.54, T1 = 1.53 ± 1.11; p = 0.005); testosterone (ng/mL: T0 = 0.34 ± 0.27, T1 = 0.24 ± 0.20; p = 0.003); hs-CRP (mg/L: T0 = 2.18 ± 2.14, T1 = 1.75 ± 1.74; p = 0.027). The other parameters did not change. Despite the home-confinement, LI based on exercise and nutrition improved cardiometabolic health in BCSs.

show abstract

“…By contrast, other studies did not observe any impact of lockdown on glycemic control [ [18] , [19] , [20] , [21] , [22] ]. Indeed, deterioration of glycemia in DM even without a national lockdown has been reported [ 23 ].…”

Section: Impact Of Covid-19 and Related Quarantine Procedures On Metabolic Riskmentioning

confidence: 66%

“…In a short-term observational study in the Netherlands, 435 people with DM (280 type 1 DM and 155 type 2 DM) HbA 1c 8-11 weeks after the start of lockdown measures compared to before showed no deterioration of glycemic control but increase in perceived stress and anxiety, weight gain and less exercise [ 18 ]. In a retrospective study in Italy (128 type 2 DM) investigating the effect of lockdown (9 March 2020 to 18 May 2020), there was significant increase in body mass index, fasting plasma glucose and HbA 1c with insulin therapy being the only significant predictor of worsening of HbA 1c [ 19 ]. From the results of another study done in Italy including 304 type 2 DM with mean age of 69 years, home confinement related to COVID-19 lockdown did not exert any significant impact on fasting plasma glucose and HbA 1c [ 20 ].…”

Section: Impact Of Covid-19 and Related Quarantine Procedures On Metabolic Riskmentioning

confidence: 99%

Influence of COVID-19 pandemic and related quarantine procedures on metabolic risk

Lim

Kong

Tuomilehto

2021

Primary Care Diabetes

View full text Add to dashboard Cite

Coronavirus disease 2019 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has changed the lives of many people across the globe. In addition to the effect of the virus on the biological functions in those infected individuals, many countries have launched government policy with additional impact of these quarantine procedures on the metabolic health of many people worldwide. This mini-review aimed to highlight current evidence regarding the influence of metabolic health due to these quarantine procedures including decrease in physical activity, changes in unhealthy eating habits, increase in stress, and provide recommendations of healthy lifestyle during COVID-19 pandemic.

show abstract

Weight change and glycemic control in type 2 diabetes patients during COVID-19 pandemic: the lockdown effect

Cited by 65 publications

References 26 publications

Impact of COVID-19 restrictions on diabetes health checks and prescribing for people with type 2 diabetes: a UK-wide cohort study involving 618 161 people in primary care

Impact of COVID-19 restrictions on diabetes health checks and prescribing for people with type 2 diabetes: a UK-wide cohort study involving 618 161 people in primary care

Effects of a Home-Based Lifestyle Intervention Program on Cardiometabolic Health in Breast Cancer Survivors during the COVID-19 Lockdown

Influence of COVID-19 pandemic and related quarantine procedures on metabolic risk

Contact Info

Product

Resources

About